Otitis Media disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

OMS MCID: OTT002 MIFTS: 78	Otitis Media (OMS) Categories: Ear diseases, Eye diseases, Genetic diseases, Neuronal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Otitis Media

MalaCards integrated aliases for Otitis Media:

Name: Otitis Media ⁵⁷ ¹¹ ⁷³ ²⁸ ⁵³ ⁵ ² ⁴³ ¹⁴ ¹⁶ ⁷¹ ⁷⁵ ³³

Opsoclonus-Myoclonus Syndrome ¹⁹ ⁵⁸ ⁵³ ⁵ ¹⁶ ⁷¹

Otitis Media, Susceptibility to ⁵⁷ ²⁸ ¹² ⁵

Oms ⁵⁷ ¹⁹ ⁵⁸ ⁷³

Kinsbourne Syndrome ¹⁹ ⁵⁸ ⁷¹

Paraneoplastic Opsoclonus-Myoclonus-Ataxia Syndrome ¹⁹ ⁵⁸

Opsoclonus-Myoclonus-Ataxia Syndrome ¹⁹ ⁵⁸

Paraneoplastic Opsoclonus-Myoclonus ¹⁹ ⁵⁸

Dancing Eye-Dancing Feet Syndrome ¹⁹ ⁵⁸

Otitis Media, Chronic/recurrent ⁵⁷ ⁷³

Ataxo-Opso-Myoclonus Syndrome ¹⁹ ⁵⁸

Dancing Eye Syndrome ¹⁹ ⁵⁸

Poma Syndrome ¹⁹ ⁵⁸

Oma Syndrome ¹⁹ ⁵⁸

Come/rom ⁵⁷ ⁷³

{otitis Media, Susceptibility to} ³⁸

Opsoclonus Myoclonus Syndrome ¹⁹

Infectious Otitis Media ⁷¹

Opsoclonus Myoclonus ⁵²

Om ⁷³

Characteristics:

Inheritance:

Autosomal dominant ⁵⁷

Prevelance:

Opsoclonus-Myoclonus Syndrome: <1/1000000 (Europe, United Kingdom) ⁵⁸

Age Of Onset:

Opsoclonus-Myoclonus Syndrome: Childhood,Infancy ⁵⁸

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Ear diseases Neuronal diseases Eye diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Diseases of the ear and mastoid process

Diseases of middle ear and mastoid

Otitis media in diseases classified elsewhere

Otitis media in other diseases classified elsewhere

Suppurative and unspecified otitis media

Otitis media, unspecified

Diseases of the nervous system

Extrapyramidal and movement disorders

Other extrapyramidal and movement disorders

Myoclonus

ICD11: ³³

Diseases of the ear or mastoid process

Diseases of middle ear or mastoid

Otitis media

Other specified otitis media

Otitis media, unspecified

Orphanet: ⁵⁸

Rare neurological diseases

Rare eye diseases

External Ids:

Disease Ontology ¹¹ DOID:10754

OMIM® ⁵⁷ 166760

ICD9CM ³⁴ 382.9

MeSH ⁴³ D010033

NCIt ⁴⁹ C34885

SNOMED-CT ⁶⁸ 65363002

ICD10 ³¹ H66.9 H67 H67.8

MESH via Orphanet ⁴⁴ D053578

ICD10 via Orphanet ³² G25.3

UMLS via Orphanet ⁷² C0393626 C1096154 C1721017

Orphanet ⁵⁸ ORPHA1183

MedGen ⁴⁰ C1833692

EFO ¹⁶ EFO_0004992 EFO_1001383

ICD11 ³³ 1079654421 1079654421/other 1079654421/unspecified

UMLS ⁷¹ C0029882 C0393626 C1096154 more

Sources

Summaries for Otitis Media

CDC: ² Ear infections can affect the ear canal or the middle ear. Acute otitis externa (AOE) is the scientific name for an infection of the ear canal, which is also called swimmer's ear. Middle ear infections are called Otitis Media, and there are two types of middle ear infections: Otitis Media with Effusion (OME) occurs when fluid builds up in the middle ear without pain, pus, fever, or other signs and symptoms of infection. Acute Otitis Media (AOM) occurs when fluid builds up in the middle ear and is often caused by bacteria, but can also be caused by viruses.

MalaCards based summary: Otitis Media, also known as opsoclonus-myoclonus syndrome, is related to suppurative otitis media and chronic purulent otitis media, and has symptoms including myoclonus and ophthalmoplegia. An important gene associated with Otitis Media is A2ML1 (Alpha-2-Macroglobulin Like 1), and among its related pathways/superpathways are Innate Immune System and Disease. The drugs Halofantrine and Montelukast have been mentioned in the context of this disorder. Affiliated tissues include eye, bone and breast, and related phenotypes are sleep disturbance and ataxia

NINDS: ⁵² Opsoclonus myoclonus is a rare neurological disorder characterized by an unsteady, trembling gait, myoclonus (brief, shock-like muscle spasms), and opsoclonus (irregular, rapid eye movements). Other symptoms may include difficulty speaking, poorly articulated speech, or an inability to speak. A decrease in muscle tone, lethargy, irritability, and malaise (a vague feeling of bodily discomfort) may also be present. Opsoclonus myoclonus may occur in association with tumors or viral infections. It is often seen in children with tumors.

GARD: ¹⁹ Opsoclonus-myoclonus syndrome (OMS) is a rare disorder that affects the nervous system. Symptoms include rapid, multi-directional eye movements (opsoclonus), quick, involuntary muscle jerks (myoclonus), uncoordinated movement (ataxia), irritability, and sleep disturbance. The disease may become chronic.

Orphanet: ⁵⁸ Opsoclonus myoclonus syndrome (OMS) is a rare neuroinflammatory disease of paraneoplastic, parainfectious or idiopathic origin, characterized by opsoclonus, myoclonus, ataxia, and behavioral and sleep disorders.

UniProtKB/Swiss-Prot: ⁷³ An inflammation of the middle ear resulting in earache, fever, hearing disturbance, and vertigo.

Disease Ontology: ¹¹ A otitis which involves inflammation of the middle ear.

Wikipedia: ⁷⁵ Otitis media is a group of inflammatory diseases of the middle ear. One of the two main types is acute... more...

More information from OMIM: 166760

Sources

Related Diseases for Otitis Media

Diseases related to Otitis Media via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1272)

#	Related Disease	Score	Top Affiliating Genes
1	suppurative otitis media	33.6	TLR4 MUC5B MUC5AC FBXO11 A2ML1
2	chronic purulent otitis media	33.5	TLR4 TLR2 MUC5B MUC5AC FBXO11 A2ML1
3	chronic atticoantral disease	33.3	TNF MUC5AC
4	adenoid hypertrophy	32.7	IL6 IL10 CXCL8
5	haemophilus influenzae	32.7	TNF TLR2 LACTB IL1B CXCL8
6	pharyngitis	32.5	TNF TLR2 LACTB IL6 IL1B CXCL8
7	allergic rhinitis	31.9	RNASE3 IL10 CXCL8 CCL11
8	rhinitis	31.9	TNF TLR4 RNASE3 IL6 IL1B IL10
9	middle ear disease	31.9	TNF TLR4 TLR2 MUC5B MUC5AC IL6
10	common cold	31.9	TNF RNASE3 MUC5AC IL6 IL1B IL10
11	meningitis	31.8	TNF TLR4 TLR2 MBL2 LACTB IL6
12	ige responsiveness, atopic	31.7	SPINK5 RNASE3 IL10
13	gastroesophageal reflux	31.7	TNF IL6 IL1B CXCL8 CCL11
14	vasculitis	31.7	TNF MBL2 IL6 IL1B IL10 CXCL8
15	exanthem	31.6	TNF IL6 IL1B IL10 CXCL8
16	viral infectious disease	31.6	TNF TLR4 TLR2 MBL2 IL6 IL1B
17	diarrhea	31.6	TNF TLR4 IL6 IL1B IL10 CXCL8
18	cartilage disease	31.5	TNF IL6 IL1B
19	conjunctivitis	31.4	TNF TLR4 RNASE3 IL6 IL10 CXCL8
20	tonsillitis	31.4	TNF TLR4 TLR2 MBL2 LACTB IL6
21	chlamydia	31.4	TNF TLR4 TLR2 MBL2 IL6 IL1B
22	allergic disease	31.4	TNF RNASE3 IL6 IL1B IL10 CXCL8
23	bacterial meningitis	31.4	TNF TLR4 TLR2 LACTB IL1B IL10
24	apnea, obstructive sleep	31.4	TNF IL6 IL1B IL10 CXCL8
25	osteomyelitis	31.4	TNF TLR4 TLR2 IL6 IL1B IL10
26	cellulitis	31.3	TNF RNASE3 LACTB IL6 IL1B CXCL8
27	encephalitis	31.3	TNF TLR2 IL6 IL1B IL10 CXCL8
28	scarlet fever	31.3	TNF IL6 IL1B
29	hypereosinophilic syndrome	31.3	RNASE3 IL10 CXCL8 CCL11
30	food allergy	31.2	TNF RNASE3 IL10 CXCL8 CCL11
31	pneumonia	31.2	TNF TLR4 TLR2 MUC5B MBL2 LACTB
32	asthma	31.2	TNF TLR4 TLR2 SPINK5 RNASE3 MUC5B
33	measles	31.2	TLR4 TLR2 IL6 IL1B
34	dental caries	31.2	MUC5B MBL2 IL6 IL1B CD79A
35	meningoencephalitis	31.1	TNF IL6 IL1B IL10 CD79A
36	hepatitis a	31.1	TNF TLR4 IL1B IL10
37	tetanus	31.1	TNF IL6 IL1B IL10 CD79A
38	dermatitis	31.1	TNF SPINK5 RNASE3 IL6 IL1B IL10
39	extrapulmonary tuberculosis	31.1	TNF TLR2 IL6 IL1B IL10 CXCL8
40	chickenpox	31.1	TNF IL6 IL1B IL10
41	respiratory failure	31.1	TNF TLR4 RNASE3 MUC5AC IL6 IL1B
42	speech and communication disorders	31.1	TNF IL6 IL1B IL10
43	intracranial hypertension	31.1	TNF IL6 IL1B
44	bronchitis	31.1	TNF TLR4 TLR2 RNASE3 LACTB IL6
45	septic arthritis	31.1	TNF TLR2 IL6 IL1B IL10 CXCL8
46	mucositis	31.1	TLR4 IL1B IL10
47	churg-strauss syndrome	31.1	TNF RNASE3 IL1B IL10 CXCL8 CCL11
48	sleep apnea	31.1	TNF IL6 IL1B IL10 CXCL8
49	aspergillosis	31.0	TNF TLR4 TLR2 MBL2 IL6 IL1B
50	bacterial conjunctivitis	31.0	TNF IL6 IL1B IL10 CXCL8

Comorbidity relations with Otitis Media via Phenotypic Disease Network (PDN):

Acute Cystitis	Bronchitis
Cholesteatoma of Middle Ear	Deficiency Anemia
Heart Disease	Hypertension, Essential
Labyrinthitis	Mastoiditis
Otitis Externa	Pneumococcal Meningitis

Graphical network of the top 20 diseases related to Otitis Media:

Sources

Symptoms & Phenotypes for Otitis Media

Human phenotypes related to Otitis Media:

⁵⁸ ³⁰ (show all 22)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	sleep disturbance ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002360
2	ataxia ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001251
3	opsoclonus ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0010543
4	cognitive impairment ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0100543
5	irritability ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000737
6	vertigo ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002321
7	neuroblastoma ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0003006
8	limb myoclonus ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0045084
9	melanoma ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002861
10	breast carcinoma ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0003002
11	encephalopathy ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001298
12	rigidity ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002063
13	small cell lung carcinoma ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0030357
14	chronic infection ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0031035
15	autoimmune antibody positivity ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0030057
16	ovarian teratoma ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0012226
17	behavioral abnormality ⁵⁸		Frequent (79-30%)
18	myoclonus ⁵⁸		Very frequent (99-80%)
19	recurrent otitis media ³⁰			HP:0000403
20	neoplasm ⁵⁸		Frequent (79-30%)
21	neoplasm of the lung ⁵⁸		Occasional (29-5%)
22	abnormal saccadic eye movements ⁵⁸		Very frequent (99-80%)

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Head And Neck Ears:
otitis media

Clinical features from OMIM®:

166760 (Updated 08-Dec-2022)

UMLS symptoms related to Otitis Media:

myoclonus; ophthalmoplegia

MGI Mouse Phenotypes related to Otitis Media:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.24	CD79A FBXO11 IL10 IL1B IL6 LACTB
2	immune system	MP:0005387	10.07	CCL11 CD79A FBXO11 IL10 IL1B IL6
3	neoplasm	MP:0002006	9.95	CD79A IL10 IL1B IL6 TLR2 TLR4
4	digestive/alimentary	MP:0005381	9.92	FBXO11 IL10 IL6 MUC5AC SCNN1B TLR2
5	respiratory system	MP:0005388	9.76	CCL11 IL10 IL6 MUC5B SCNN1B TLR2
6	skeleton	MP:0005390	9.7	FBXO11 IL10 IL1B IL6 LACTB MBL2
7	hematopoietic system	MP:0005397	9.4	CCL11 CD79A FBXO11 IL10 IL1B IL6

Sources

Drugs & Therapeutics for Otitis Media

Drugs for Otitis Media (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 204)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Halofantrine

Approved

Phase 4

69756-53-2

37393

Montelukast

Approved

Phase 4

158966-92-8

5281040

Azithromycin

Approved

Phase 4

83905-01-5

447043

Dexlansoprazole

Approved, Investigational

Phase 4

138530-94-6

9578005

Lansoprazole

Approved, Investigational

Phase 4

103577-45-3

3883

Amoxicillin

Approved, Vet_approved

Phase 4

26787-78-0

33613

Cetirizine

Approved

Phase 4

83881-51-0

2678

Racephedrine

Approved, Experimental

Phase 4

299-42-3, 90-82-4, 90-81-3

5032 9294 7028

Levocetirizine

Approved

Phase 4

130018-77-8

1549000

Prednisolone phosphate

Approved, Vet_approved

Phase 4

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 4

52-21-1

Prednisolone

Approved, Vet_approved

Phase 4

50-24-8

4894 5755

Phenylephrine

Approved

Phase 4

59-42-7

6041

Cefpodoxime

Approved, Vet_approved

Phase 4

82619-04-3, 80210-62-4

6335986

Methylprednisolone hemisuccinate

Approved

Phase 4

2921-57-5

1875

Histamine

Approved, Investigational

Phase 4

51-45-6

774

Methylprednisolone

Approved, Vet_approved

Phase 4

83-43-2

4159 6741

Oxymetazoline

Approved, Investigational

Phase 4

1491-59-4

4636

Mometasone furoate

Approved, Investigational, Vet_approved

Phase 4

83919-23-7

4240 441336

Clavulanic acid

Approved, Vet_approved

Phase 4

58001-44-8

5280980

Strawberry

Approved

Phase 4

Cefdinir

Approved

Phase 4

91832-40-5

6915944

Aluminium phosphate

Approved, Investigational

Phase 4

7784-30-7

Morphine

Approved, Investigational

Phase 4

57-27-2

5288826

Levofloxacin

Approved, Investigational

Phase 4

100986-85-4

149096

Ofloxacin

Approved

Phase 4

82419-36-1

4583

Ketorolac

Approved

Phase 4

74103-06-3, 66635-83-4

3826

Sodium citrate

Approved, Investigational

Phase 4

68-04-2

23431961

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4

437-38-7

3345

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 4

77-92-9

311

Prednisolone hemisuccinate

Experimental

Phase 4

2920-86-7

4897

Anesthetics

Phase 4

Leukotriene Antagonists

Phase 4

Anti-Asthmatic Agents

Phase 4

Anti-Ulcer Agents

Phase 4

Antacids

Phase 4

Proton Pump Inhibitors

Phase 4

Cardiotonic Agents

Phase 4

Cefpodoxime proxetil

Phase 4

2645

Adrenergic alpha-Agonists

Phase 4

Adrenergic Agonists

Phase 4

Adrenergic Agents

Phase 4

Anti-Allergic Agents

Phase 4

Vasoconstrictor Agents

Phase 4

Histamine phosphate

Phase 4

51-74-1

134614

Histamine H1 Antagonists, Non-Sedating

Phase 4

Histamine H1 Antagonists

Phase 4

Methylprednisolone Acetate

Phase 4

584547

Histamine Antagonists

Phase 4

Mydriatics

Phase 4

Interventional clinical trials:

(show top 50) (show all 259)

#	Name	Status	NCT ID	Phase	Drugs
1	The Influence of The Ear Popper on Serous Otitis Media and on the Accompanying Conductive Hearing Loss in Children	Unknown status	NCT00393159	Phase 4
2	Phase 4 Efficacy Study of Antimicrobials in the Treatment of Acute Otitis Media in Young Children	Unknown status	NCT00299455	Phase 4	amoxicillin-clavulanate;Placebo
3	A Pilot Study to Evaluate the Efficacy of Montelukast in the Treatment of Acute Otitis Media (AOM) in Children	Completed	NCT00189462	Phase 4	Montelukast;Placebo
4	Amoxycillin Versus Placebo for Resolution of Otitis Media With Effusion and Prevention of Acute Otitis Media With Perforation in Aboriginal Infants: a Randomised Controlled Trial.	Completed	NCT00539149	Phase 4	Amoxycillin;Placebo equivalent to amoxycillin
5	Efficacy and Cost Analysis of Steroids in Treatment of Otitis Media With Effusion (OME) Compared to That of Combination of Antibiotic, Antihistaminic, and Nasal Decongestant	Completed	NCT03590912	Phase 4	Mometasone 50 Mcg/Inh Nasal Spray;Antibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%);Steroid Drug (prednisolone)
6	Role of Empiric Anti-reflux Therapy in Pediatric Otitis Media With Effusion - a Pilot Study	Completed	NCT01082029	Phase 4	Lansoprazole;Placebo
7	Efficacy of Antimicrobials in Young Children With Acute Otitis Media (AOM)	Completed	NCT00377260	Phase 4	amoxicillin-clavulanate;Placebo
8	A Multicenter, Open-label, Non-comparative Phase IV Clinical Study to Evaluate the Safety and Clinical Efficacy of Augmentin Extra Strength (ES)-600 in Children With Acute Otitis Media (AOM) in India	Completed	NCT04600752	Phase 4	Augmentin (ES)-600
9	Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)	Completed	NCT00419380	Phase 4	dornase alfa (Pulmozyme®)
10	A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media	Completed	NCT00645112	Phase 4	cefdinir (Omnicef);azithromycin
11	A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin/Clavulanate in Pediatric Subjects With Acute Otitis Media	Completed	NCT00644943	Phase 4	cefdinir (Omnicef);amoxicillin
12	Postoperative Analgesic and Behavioral Effects of Intranasal Fentanyl, Intravenous Morphine and Intramuscular Morphine in Pediatric Patients Undergoing Bilateral Myringotomy and Placement of Ventilating Tubes	Completed	NCT01244126	Phase 4	Intranasal fentanyl;morphine IM;IV morphine
13	Clinical Trial for the Assessment of Delayed Antibiotic Treatment in the Non-complicated Acute Respiratory Tract Infections in Pediatric (Study DAP-Pediatrics)	Completed	NCT01800747	Phase 4
14	Pneumococcal Conjugate Vaccine (PCV) Schedules for the Northern Territory (NT): Randomised Controlled Trial of Booster Vaccines to Broaden and Strengthen Protection From Invasive and Mucosal Infections.	Completed	NCT01735084	Phase 4
15	A Randomised Controlled Trial of Pneumococcal Conjugate Vaccines Synflorix and Prevenar13 in Sequence or Alone in High-risk Indigenous Infants (PREV-IX_COMBO): Immunogenicity, Carriage and Otitis Media Outcomes	Completed	NCT01174849	Phase 4	Synflorix;Prevenar13;COMBO
16	Effect of Antimicrobial Treatment of Acute Otitis Media on the Intestinal Microbiome in Children: A Randomized Controlled Trial	Completed	NCT02935374	Phase 4	Amoxicillin;Amoxicillin-Potassium Clavulanate;Macrolide
17	Does the Use of Topical Otic Drops at the Time of Tympanostomy Tube Placement Improve Outcomes When no Middle Ear Effusion is Present at the Time of Surgery	Recruiting	NCT03655665	Phase 4	Ofloxacin otic solution
18	Prospective, Randomized, Allocation-Concealed, Blinded Study Designed to Compare Ketorolac Sublingual and Fentanyl Intranasal in Pain Control for Bilateral Myringotomy and Tubes (BMT) Placement in Children	Recruiting	NCT02653742	Phase 4	Ketorolac;Fentanyl
19	Otiprio Versus Ciprodex to Reduce Tympanostomy Tube Failure	Withdrawn	NCT03347461	Phase 4	Otiprio;Ciprodex
20	N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media	Withdrawn	NCT00956748	Phase 4	Ciprodex;Ciprodex and 2% NAC
21	PneuMum: A Randomised Controlled Trial of Pneumococcal Polysaccharide Vaccination for Aboriginal and Torres Strait Islander Mothers to Protect Their Babies From Ear Disease	Unknown status	NCT00310349	Phase 3
22	A Study of Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines to Inform Policy Regarding Pneumococcal Vaccination of Papua New Guinean Children	Unknown status	NCT01619462	Phase 3
23	A Randomized Control Study of the Outcomes of Mastoidotympanoplasty Versus Tympanoplasty in Quiescent Tubotympanic Otitis Media	Unknown status	NCT00271778	Phase 3
24	Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays: a Randomized Placebo-controlled Study	Completed	NCT00279916	Phase 3	Triamcinolone acetonide nasal spray;Placebo nasal spray
25	A Prospective, Single-arm, Multicenter Study to Evaluate Effectiveness and Safety of Tympanostomy Tube Placement Using the Tula Iontophoresis and Tube Delivery Systems for Children in an Office Setting.	Completed	NCT03323736	Phase 3
26	Safety and Efficacy of EXE844 Otic Suspension in the Treatment of Otitis Media at Time of Tympanostomy Tube Insertion	Completed	NCT02432105	Phase 3	EXE844 Sterile Otic Suspension, 0.3%
27	Safety and Efficacy of EXE844 Otic Suspension in the Treatment of Otitis Media at Time of Tympanostomy Tube Insertion	Completed	NCT02436304	Phase 3	EXE844 Sterile Otic Suspension, 0.3%
28	A Clinical Study of the Acclarent Tympanostomy Tube Delivery System for the Treatment of Patients Requiring Tympanostomy Tube Insertion for Otitis Media	Completed	NCT01202578	Phase 2, Phase 3
29	Effects of 100% Medical Grade Manuka Honey on Re-epithelialization Post Tympanoplasty in the Case of Mucosal Type Chronic Suppurative Otitis Media (CSOM) - A Prospective Double-blinded Randomized Controlled Trial	Completed	NCT05605262	Phase 2, Phase 3	Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey
30	Prospective, Randomized, Double-Blind, Sham-Controlled, Multicenter, P3 Study of OTO-201 Given as a Single IT Injection For Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement	Completed	NCT01949155	Phase 3	OTO-201;Sham
31	Prospective, Randomized, Double-Blind, Sham-Controlled, Multicenter, P3 Study of OTO-201 Given as a Single IT Injection For Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement	Completed	NCT01949142	Phase 3	OTO-201;Sham
32	PneuMum: A Randomised Controlled Trial of Pneumococcal Polysaccharide Vaccination for Aboriginal and Torres Strait Islander Mothers to Protect Their Babies From Ear Disease	Completed	NCT00714064	Phase 3
33	Monteleukast Versus Inhaled Mometasone for Treatment of Otitis Media With Effusion in Children	Completed	NCT02541760	Phase 3	Monteleukast;Mometasone
34	Oral Amoxicillin-clavulanate in Treating Acute Otitis Media in Children: Randomized Double-blind Placebo-controlled Study Including Daily Monitoring With Tympanometry	Completed	NCT01244581	Phase 3	Amoxicillin-clavulanate;Placebo
35	Safety and Efficacy of Sinuclean Nebules 45 (Class 1 Medical Device) in the Treatment of Pediatric Exudative Otitis Media, Randomized, Double Blind, Comparative, Parallel Study	Completed	NCT02858388	Phase 3
36	Video, Ear Infections & Antibiotic Stewardship: Knowledge Translation Upon Emergency Department Discharge	Completed	NCT02703389	Phase 3
37	A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years	Completed	NCT02044341	Phase 3	AR01;Glycerin ear drops
38	Efficacy Trial in Finnish Children of Two Pneumococcal Conjugate Vaccines (PncCRM and PncOMPC) for Prevention of Acute Otitis Media Due to Pneumococcal Serotypes in the Vaccines	Completed	NCT00378417	Phase 3
39	An Open-Label, Safety and Efficacy Study of Cefdinir Oral Suspension, 25 mg/kg Once Daily, in Pediatric Subjects With Acute Otitis Media	Completed	NCT00645203	Phase 2, Phase 3	cefdinir
40	Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children 6-23 Months With Acute Otitis Media	Completed	NCT02630992	Phase 3	Amoxicillin-Clavulanate potassium
41	Evaluation of the Safety, Efficacy, Pharmacokinetics, and Acceptability of HMR3647 20 mg/kg qd for 5 Days With Acute Otitis Media (AOM) in Children (Multicenter, Open Label, Non Comparative Study)	Completed	NCT00638534	Phase 3	Telithromycin (HMR3647)
42	An 8-Week, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Administration in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes	Completed	NCT02600559	Phase 3	OTO-201 (ciprofloxacin)
43	A Pilot, Multicenter, Open Label, Non Comparative Study of the Safety and Efficacy of Floxin Otic Solution in the Treatment of Acute Otitis Media Twice Daily for Seven Days in Children With Tympanostomy Tubes	Completed	NCT00781521	Phase 3	ofloxacin otic solution 0.3%
44	A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Amoxicillin/Clavulanate Potassium (Augmentin ES-600 Trademark) for the Treatment of Acute Otitis Media in Children Undergoing Diagnostic Tympanocentesis	Completed	NCT00643292	Phase 3	amoxicillin/clavulanate postassium (Augmentin ES-600);azithromycin SR
45	A Multicenter, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Levofloxacin in the Treatment of Children Who Have Recurrent and/or Persistent Acute Otitis Media	Completed	NCT00051753	Phase 3	levofloxacin; amoxicillin/clavulanate
46	An Open-Label Study of Levofloxacin to Evaluate Bacteriologic Outcome in the Treatment of Children Who Are at Risk for Acute Otitis Media That is Difficult to Treat	Completed	NCT00044473	Phase 3	levofloxacin
47	Comparison of Treatment Satisfaction and Treatment Adherence of a Novel Application Form "Dose Sipping Technology" (DST) of Oral Clarithromycin vs. Clarithromycin Syrup in Children Suffering From Acute Otitis Media, Tonsillitis, Pharyngitis, or Acute Bacterial Bronchitis (DoSe iT)	Completed	NCT04016051	Phase 3	Clarithromycin DST (125 mg);Clarithromycin DST (187.5 mg);Clarithromycin DST (250 mg);Clarithromycin Syrup (125 mg);Clarithromycin Syrup (187.5 mg);Clarithromycin Syrup (250 mg)
48	Safety and Efficacy of a Topical Otic Formulation in the Treatment of Acute Otitis Media With Otorrhea Through Tympanostomy Tubes (AOMT)	Completed	NCT00579189	Phase 3	Moxidex otic solution;Moxifloxacin otic solution
49	Efficacy and Safety of an Herbal-Based Medication vs. Placebo in Preventing Acute Otitis Media in Children at High Risk of Recurrence: A Placebo Controlled, Randomized, Double-blinded Parallel-Group Comparison for Superiority	Completed	NCT02345447	Phase 3	Herbal-based medication;Placebo
50	Phase III, Multicenter, Randomized, Double-Blind, Placebo- Controlled Parallel-Designed Evaluation to Assess Safety and Efficacy of Topical Benzocaine for Treatment of Pain Associated With Acute Otitis Media in Children Ages 5 to 12 Years	Completed	NCT03116737	Phase 3	Benzocaine Otic Solution;Placebo

Search NIH Clinical Center for Otitis Media

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

acetyl sulfisoxazole

Antipyrine

Benzocaine

BENZOCAINE PWDR

CEFTIBUTEN DIHYDRATE

Sulfisoxazole

Sulfisoxazole Diolamine

Cochrane evidence based reviews: otitis media

Sources

Genetic Tests for Otitis Media

Genetic tests related to Otitis Media:

#	Genetic test	Affiliating Genes
1	Otitis Media, Susceptibility to ²⁸	A2ML1
2	Otitis Media ²⁸

Sources

Anatomical Context for Otitis Media

Organs/tissues related to Otitis Media:

MalaCards : Eye, Bone, Breast, Lung, Tonsil, Brain, Neutrophil

Sources

Publications for Otitis Media

Articles related to Otitis Media:

(show top 50) (show all 22913)

#	Title	Authors	PMID	Year
1	Genetic and Environmental Determinants of Otitis Media in an Indigenous Filipino Population. ⁶² ⁵⁷ ⁵	Santos-Cortez RL...Abes GT	27484237	2016
2	Otitis media susceptibility and shifts in the head and neck microbiome due to SPINK5 variants. ⁶² ⁵	Frank DN...Santos-Cortez RLP	32709676	2021
3	A2ML1 and otitis media: novel variants, differential expression, and relevant pathways. ⁶² ⁵	Larson ED...Santos-Cortez RLP	31009165	2019
4	Rare A2ML1 variants confer susceptibility to otitis media. ⁶² ⁵⁷	Santos-Cortez RL...Leal SM	26121085	2015
5	Eya4-deficient mice are a model for heritable otitis media. ⁶² ⁵⁷	Depreux FF...Seidman JG	18219393	2008
6	Chronic and recurrent otitis media: a genome scan for susceptibility loci. ⁶² ⁵⁷	Daly KA...Rich SS	15514890	2004
7	The heritability of otitis media: a twin and triplet study. ⁶² ⁵⁷	Casselbrant ML...Ferrell RE	10591333	1999
8	Susceptibility to otitis media: strong evidence that genetics plays a role. ⁶² ⁵⁷	Ehrlich GD...Post JC	10591340	1999
9	Familial predisposition for otitis media in Apache Indians at Canyon Day, Arizona. ⁶² ⁵⁷	Todd NW	3569876	1987
10	Mucin gene polymorphisms in otitis media patients. ⁵³ ⁶²	Ubell ML...Kerschner JE	19718741	2010
11	[Evaluation of percentage of lymphocytes B with expression of co-receptors CD 40, CD22 and CD72 in hypertrophied adenoid at children with otitis media with effusion]. ⁵³ ⁶²	Wysocka J...Hassmann-Poznanska E	20198985	2009
12	Glucocorticoids inhibit nontypeable Haemophilus influenzae-induced MUC5AC mucin expression via MAPK phosphatase-1-dependent inhibition of p38 MAPK. ⁵³ ⁶²	Komatsu K...Li JD	18957283	2008
13	Toll-like receptors 2 and 4 and their mutations in patients with otitis media and middle ear effusion. ⁵³ ⁶²	Lee YC...Yeo SG	19434266	2008
14	Neurometabolic effects of ACTH on free amino compounds in opsoclonus-myoclonus syndrome. ⁵³ ⁶²	Pranzatelli MR...Creer M	18991196	2008
15	Antibodies to pneumococcal surface protein A families 1 and 2 in serum and saliva of children and the risk of pneumococcal acute otitis media. ⁵³ ⁶²	Simell B...Kayhty H	18008233	2007
16	Association of CD14 promoter polymorphism with otitis media and pneumococcal vaccine responses. ⁵³ ⁶²	Wiertsema SP...Sanders EA	16893989	2006
17	Functional polymorphisms in the mannan-binding lectin 2 gene: effect on MBL levels and otitis media. ⁵³ ⁶²	Wiertsema SP...Rijkers GT	16750996	2006
18	[The measuring of ECP and IgE in middle ear effusion of patients with otitis media of effusion]. ⁵³ ⁶²	Tian J...Liu H	16883790	2006
19	Total serum IgE and IgE antibodies specific to house dust mite found in two aged-matched cohorts of children with and without otitis media with effusion. ⁵³ ⁶²	Coulson CJ...Drayson MT	16620332	2006
20	Up-regulation of MUC5AC and MUC5B mucin genes in nasopharyngeal respiratory mucosa and selective up-regulation of MUC5B in middle ear in pediatric otitis media with effusion. ⁵³ ⁶²	Elsheikh MN...Mahfouz ME	16540890	2006
21	Role of mannose-binding lectin (MBL2) genotyping in predicting the risk of recurrent otitis media (rOM). ⁵³ ⁶²	Nuytinck L...Govaerts P	16893079	2006
22	Childhood levels of immunoglobulins and mannan-binding lectin in relation to infections and allergy. ⁵³ ⁶²	Thorarinsdottir HK...Arason GJ	15882439	2005
23	Immunological status in the aetiology of recurrent otitis media with effusion: serum immunoglobulin levels, functional mannose-binding lectin and Fc receptor polymorphisms for IgG. ⁵³ ⁶²	Straetemans M...Zielhuis GA	15742161	2005
24	Immunological parameters in girls with Turner syndrome. ⁵³ ⁶²	Stenberg AE...Hultcrantz M	15563731	2004
25	IL-5 and eotaxin levels in middle ear effusion and blood from asthmatics with otitis media with effusion. ⁵³ ⁶²	Nonaka M...Yagi T	12737295	2003
26	Glucocorticoids synergistically enhance nontypeable Haemophilus influenzae-induced Toll-like receptor 2 expression via a negative cross-talk with p38 MAP kinase. ⁵³ ⁶²	Shuto T...Li JD	11867630	2002
27	Human lactoferrin proteolytic activity: analysis of the cleaved region in the IgA protease of Haemophilus influenzae. ⁵³ ⁶²	Plaut AG...St Geme JW	11163480	2000
28	Increased expression of major basic protein (MBP) and interleukin-5(IL-5) in middle ear biopsy specimens from atopic patients with persistent otitis media with effusion. ⁵³ ⁶²	Wright ED...Hamid Q	11077335	2000
29	[Immunology in the medical practice. XXVII. Mannose-binding lectin, an important link for nonspecific or hereditary immune reaction]. ⁵³ ⁶²	van Deuren M	10897301	2000
30	Eosinophils and neutrophils in biopsies from the middle ear of atopic children with otitis media with effusion. ⁵³ ⁶²	Amin K...Seveus L	10669113	1999
31	The influence of karyotype on the auricle, otitis media and hearing in Turner syndrome. ⁵³ ⁶²	Barrenas ML...Hanson C	10575123	1999
32	Evidence of possible localized specific immunoglobulin E production in middle ear fluid as demonstrated by ELISA testing. ⁵³ ⁶²	Hurst DS...Ramanarayanan MP	10471862	1999
33	Microbial factors leading to recurrent upper respiratory tract infections. ⁵³ ⁶²	Brook I	9727652	1998
34	Monoaminergic effects of high-dose corticotropin in corticotropin-responsive pediatric opsoclonus-myoclonus. ⁵³ ⁶²	Pranzatelli MR...Taff IP	9613746	1998
35	Eosinophil cationic protein in mucosal biopsies from patients with allergy and otitis media with effusion. ⁵³ ⁶²	Hurst DS...Fredens K	9230321	1997
36	Association of otitis media with effusion and allergy as demonstrated by intradermal skin testing and eosinophil cationic protein levels in both middle ear effusions and mucosal biopsies. ⁵³ ⁶²	Hurst DS	8822719	1996
37	Levels of eosinophil cationic protein and myeloperoxidase from chronic middle ear effusion in patients with allergy and/or acute infection. ⁵³ ⁶²	Hurst DS...Venge P	8643262	1996
38	Mannan-binding protein--levels in plasma and upper-airways secretions and frequency of genotypes in children with recurrence of otitis media. ⁵³ ⁶²	Garred P...Svejgaard A	8403525	1993
39	The presence of eosinophil cationic protein in middle ear effusion. ⁵³ ⁶²	Hurst DS...Venge P	8516010	1993
40	Correlation between serum immunoglobulin A concentrations and allergic manifestations in infants. ⁵³ ⁶²	Ludviksson BR...Valdimarsson H	1625088	1992
41	Sulbactam/ampicillin in the treatment of otitis and sinusitis. ⁵³ ⁶²	Nicoletti G...Raso F	2060691	1991
42	The role of bacterial adherence in otitis media with effusion. ⁵³ ⁶²	Shimamura K...Mogi G	2206498	1990
43	Prospective study about the incidence of B lactamase producing bacteriae in otitis media in the population of the emergency room of the University Pediatric Hospital. ⁵³ ⁶²	Colon I...Garcia H	2375816	1990
44	Warm-season temperatures and emergency department visits among children with health insurance. ⁶²	Stowell JD...Wellenius GA	36337257	2023
45	Unified Airway Disease: Future Directions. ⁶²	Ahmad JG...Luong AU	36410990	2023
46	Epidemiological characteristics and antibiotic resistance mechanisms of Streptococcus pneumoniae: An updated review. ⁶²	Li L...Sun H	36244081	2023
47	Role of mastoid pneumatization in predicting tympanoplasty results: Will it have the same importance in different age groups? ⁶²	Costa JR...Meireles L	36334419	2023
48	Otomycosis caused by the cryptic and emerging species Aspergillus sydowii: two case reports. ⁶²	Buonafina-Paz MD...Neves RP	36382573	2022
49	Combined Electric acoustic stimulation in a patient with otitis media with antineutrophil cytoplasmic antibody-associated vasculitis. ⁶²	Nakamura T...Matsuda Y	33962817	2022
50	Outpatient Antibiotic Prescribing for 357,390 Children With Otitis Media. ⁶²	Csonka P...Korppi M	36102742	2022

Sources

Genes for Otitis Media

Genes related to Otitis Media (2 elite genes):

(show top 50) (show all 57)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	A2ML1	Alpha-2-Macroglobulin Like 1	Protein Coding	1108.84	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ Susceptibility factor ⁵⁷ Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)	31009165 27484237
2	SDHA	Succinate Dehydrogenase Complex Flavoprotein Subunit A	Protein Coding	400	Pathogenic ⁵
3	SPINK5	Serine Peptidase Inhibitor Kazal Type 5	Protein Coding	36.99	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	32709676
4	SCNN1B	Sodium Channel Epithelial 1 Subunit Beta	Protein Coding	29.46	Likely pathogenic ⁵ DISEASES inferred ¹⁴
5	FBXO11	F-Box Protein 11	Protein Coding	25.28	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
6	MUC5AC	Mucin 5AC, Oligomeric Mucus/Gel-Forming	Protein Coding	21.27	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19718741 18957283 16540890
7	RNASE3	Ribonuclease A Family Member 3	Protein Coding	18.99	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16883790 8516010 9230321 (more) 8643262 10669113 8822719
8	MBL2	Mannose Binding Lectin 2	Protein Coding	18.58	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8403525 15742161 16750996 (more) 15882439 11077335 16893079 10897301
9	OMS	Otitis Media, Susceptibility To	Genetic Locus	17.95	GeneCards inferred via : Publications Gene name (show sections)
10	CD79A	CD79a Molecule	Protein Coding	17.89	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15882439 1625088 18008233 (more) 20198985 15563731 2206498
11	TLR2	Toll Like Receptor 2	Protein Coding	17.66	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11867630 19434266
12	LACTB	Lactamase Beta	Protein Coding	17.02	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	2060691 2375816 9727652
13	TNF	Tumor Necrosis Factor	Protein Coding	15.81	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	IL1B	Interleukin 1 Beta	Protein Coding	15.8	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	IL6	Interleukin 6	Protein Coding	15.6	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	15.45	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
17	MUC5B	Mucin 5B, Oligomeric Mucus/Gel-Forming	Protein Coding	15.29	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
18	TLR4	Toll Like Receptor 4	Protein Coding	15.27	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
19	IL10	Interleukin 10	Protein Coding	15.23	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
20	CCL11	C-C Motif Chemokine Ligand 11	Protein Coding	14.99	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12737295
21	CRP	C-Reactive Protein	Protein Coding	14.87	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
22	IL4	Interleukin 4	Protein Coding	14.76	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
23	SFTPA1	Surfactant Protein A1	Protein Coding	14.51	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
24	IL5	Interleukin 5	Protein Coding	14.39	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
25	MPO	Myeloperoxidase	Protein Coding	14.37	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
26	ALB	Albumin	Protein Coding	14.28	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
27	IFNG	Interferon Gamma	Protein Coding	14.16	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
28	SFTPA2	Surfactant Protein A2	Protein Coding	14.07	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
29	IL17A	Interleukin 17A	Protein Coding	13.85	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
30	EYA4	EYA Transcriptional Coactivator And Phosphatase 4	Protein Coding	13.83	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
31	IL1A	Interleukin 1 Alpha	Protein Coding	13.79	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
32	ICAM1	Intercellular Adhesion Molecule 1	Protein Coding	13.77	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
33	IGHE	Immunoglobulin Heavy Constant Epsilon	Protein Coding	13.66	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16620332 10471862 16883790 (more) 1625088
34	C3	Complement C3	Protein Coding	13.51	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
35	ELANE	Elastase, Neutrophil Expressed	Protein Coding	13.47	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
36	IL2	Interleukin 2	Protein Coding	13.46	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
37	MUC4	Mucin 4, Cell Surface Associated	Protein Coding	13.38	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
38	IL13	Interleukin 13	Protein Coding	13.3	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
39	TGIF1	TGFB Induced Factor Homeobox 1	Protein Coding	13.21	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
40	SPAG6	Sperm Associated Antigen 6	Protein Coding	13.2	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
41	FUT2	Fucosyltransferase 2	Protein Coding	13.19	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
42	CCL5	C-C Motif Chemokine Ligand 5	Protein Coding	13.1	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
43	TLR7	Toll Like Receptor 7	Protein Coding	13.07	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
44	CSF3	Colony Stimulating Factor 3	Protein Coding	12.95	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
45	CCL2	C-C Motif Chemokine Ligand 2	Protein Coding	12.78	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
46	TLR5	Toll Like Receptor 5	Protein Coding	12.76	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
47	TLR1	Toll Like Receptor 1	Protein Coding	12.71	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
48	CDHR3	Cadherin Related Family Member 3	Protein Coding	12.7	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
49	KDM6A	Lysine Demethylase 6A	Protein Coding	12.68	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
50	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	12.65	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)

Sources

Variations for Otitis Media

ClinVar genetic disease variations for Otitis Media:

⁵ (show all 28)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	A2ML1	NM_144670.6(A2ML1):c.4061+1G>C	SNV	Pathogenic Likely Pathogenic	617554	rs202067416	GRCh37: 12:9020954-9020954 GRCh38: 12:8868358-8868358
2	SDHA	NM_004168.4(SDHA):c.1534C>T (p.Arg512Ter)	SNV	Pathogenic	371805	rs748089700	GRCh37: 5:240574-240574 GRCh38: 5:240459-240459
3	SPINK5	NM_006846.4(SPINK5):c.1682A>G (p.Glu561Gly)	SNV	Likely Pathogenic	918078	rs1753847242	GRCh37: 5:147488390-147488390 GRCh38: 5:148108827-148108827
4	SCNN1B	NM_000336.3(SCNN1B):c.1609C>T (p.Leu537Phe)	SNV	Likely Pathogenic	1707413		GRCh37: 16:23391808-23391808 GRCh38: 16:23380487-23380487
5	A2ML1	NM_144670.6(A2ML1):c.2478_2485dup (p.Ser829fs)	DUP	Risk Factor	217306	rs863224951	GRCh37: 12:9004818-9004819 GRCh38: 12:8852222-8852223
6	A2ML1	NM_144670.6(A2ML1):c.10C>T (p.Gln4Ter)	SNV	Likely Pathogenic Likely Pathogenic	617555	rs1409944554	GRCh37: 12:8975257-8975257 GRCh38: 12:8822661-8822661
7	A2ML1	NM_144670.6(A2ML1):c.1308A>C (p.Gln436His)	SNV	Uncertain Significance Uncertain Significance	617557	rs780743143	GRCh37: 12:8995789-8995789 GRCh38: 12:8843193-8843193
8	A2ML1	NM_144670.6(A2ML1):c.1683G>C (p.Gln561His)	SNV	Uncertain Significance Uncertain Significance	626340	rs1565476223	GRCh37: 12:8998818-8998818 GRCh38: 12:8846222-8846222
9	A2ML1	NM_144670.6(A2ML1):c.2012T>C (p.Leu671Pro)	SNV	Uncertain Significance Uncertain Significance	617558	rs1465018225	GRCh37: 12:9001494-9001494 GRCh38: 12:8848898-8848898
10	A2ML1	NM_144670.6(A2ML1):c.2228C>T (p.Pro743Leu)	SNV	Uncertain Significance Uncertain Significance	626342	rs1565479896	GRCh37: 12:9002864-9002864 GRCh38: 12:8850268-8850268
11	A2ML1	NM_144670.6(A2ML1):c.2329G>A (p.Gly777Arg)	SNV	Uncertain Significance Uncertain Significance	617559	rs201288888	GRCh37: 12:9004474-9004474 GRCh38: 12:8851878-8851878
12	A2ML1	NM_144670.6(A2ML1):c.2545G>T (p.Asp849Tyr)	SNV	Uncertain Significance Uncertain Significance	626343	rs1408810942	GRCh37: 12:9004887-9004887 GRCh38: 12:8852291-8852291
13	A2ML1	NM_144670.6(A2ML1):c.2971G>C (p.Ala991Pro)	SNV	Uncertain Significance Uncertain Significance	626344	rs1565484901	GRCh37: 12:9009882-9009882 GRCh38: 12:8857286-8857286
14	A2ML1	NM_144670.6(A2ML1):c.3491C>T (p.Ala1164Val)	SNV	Uncertain Significance Uncertain Significance	626345	rs1565487941	GRCh37: 12:9013882-9013882 GRCh38: 12:8861286-8861286
15	A2ML1	NM_144670.6(A2ML1):c.971-8C>T	SNV	Uncertain Significance Uncertain Significance	617556	rs780868782	GRCh37: 12:8991701-8991701 GRCh38: 12:8839105-8839105
16	A2ML1	NM_144670.6(A2ML1):c.2677C>T (p.Arg893Ter)	SNV	Uncertain Significance	217310	rs199651558	GRCh37: 12:9006810-9006810 GRCh38: 12:8854214-8854214
17	A2ML1	NM_144670.6(A2ML1):c.2197T>C (p.Phe733Leu)	SNV	Uncertain Significance Uncertain Significance	384690	rs117213221	GRCh37: 12:9002833-9002833 GRCh38: 12:8850237-8850237
18	A2ML1	NM_144670.6(A2ML1):c.4061+1G>A	SNV	Uncertain Significance	696412	rs202067416	GRCh37: 12:9020954-9020954 GRCh38: 12:8868358-8868358
19	PLG	NM_000301.5(PLG):c.782G>A (p.Arg261His)	SNV	Uncertain Significance	692201	rs4252187	GRCh37: 6:161137790-161137790 GRCh38: 6:160716758-160716758
20	PLG	NM_000301.5(PLG):c.2045T>A (p.Ile682Asn)	SNV	Uncertain Significance	692203	rs147175166	GRCh37: 6:161162369-161162369 GRCh38: 6:160741337-160741337
21	PLG	NM_000301.5(PLG):c.1481C>T (p.Ala494Val)	SNV	Uncertain Significance	692204	rs4252128	GRCh37: 6:161152819-161152819 GRCh38: 6:160731787-160731787
22	A2ML1	NM_144670.6(A2ML1):c.3676_3677del (p.Ala1226fs)	DEL	Uncertain Significance	413822	rs144686314	GRCh37: 12:9016563-9016564 GRCh38: 12:8863967-8863968
23	A2ML1	NM_144670.6(A2ML1):c.164C>T (p.Thr55Ile)	SNV	Uncertain Significance Uncertain Significance	626339	rs999028234	GRCh37: 12:8975879-8975879 GRCh38: 12:8823283-8823283
24	A2ML1	NM_144670.6(A2ML1):c.2189G>A (p.Arg730His)	SNV	Uncertain Significance Uncertain Significance	626341	rs200346409	GRCh37: 12:9002825-9002825 GRCh38: 12:8850229-8850229
25	A2ML1	NM_144670.6(A2ML1):c.2713-8C>A	SNV	Uncertain Significance Uncertain Significance	241896	rs184386564	GRCh37: 12:9007368-9007368 GRCh38: 12:8854772-8854772
26	PLG	NM_000301.5(PLG):c.112A>G (p.Lys38Glu)	SNV	Benign	13583	rs73015965	GRCh37: 6:161127501-161127501 GRCh38: 6:160706469-160706469
27	A2ML1	NM_144670.6(A2ML1):c.3364C>T (p.Arg1122Trp)	SNV	Benign	384669	rs1860967	GRCh37: 12:9013755-9013755 GRCh38: 12:8861159-8861159
28	PLG	NM_000301.5(PLG):c.1414G>A (p.Asp472Asn)	SNV	Benign	692202	rs4252125	GRCh37: 6:161152240-161152240 GRCh38: 6:160731208-160731208

Sources

Expression for Otitis Media

Genes differentially expressed in tissues of Otitis Media patients vs. healthy controls: ³⁵

#	Gene	Description	Tissue	Up/Dn	Fold Change (log2)	P value
1	PNLIPRP3	pancreatic lipase related protein 3	Blood	-	6.47	0.003
2	FAM20A	FAM20A golgi associated secretory pathway pseudokinase	Blood	+	3.09	0.015

Search GEO for disease gene expression data for Otitis Media.

Sources

Pathways for Otitis Media

Pathways related to Otitis Media according to GeneCards Suite gene sharing:

(show top 50) (show all 51)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.95	CCL11 CD79A CXCL8 FBXO11 IL10 IL1B
2	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.79	TLR4 TLR2 MUC5B MUC5AC MBL2 IL6
3	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.42	CCL11 CXCL8 IL10 IL1B IL6 TLR2
4	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.89	TNF TLR4 TLR2 MBL2 IL6 IL1B
5	NF-KappaB Family Pathway ⁶⁴ Show member pathways NF-KappaB (p50-p65) Pathway ⁶⁴	12.71	IL1B IL6 TLR2 TLR4 TNF
6	IL-1 Family Signaling Pathways ⁶⁵ Show member pathways IL1 signaling pathway ⁶⁷ Immune response IL-1 signaling pathway ²² Interleukin-1 (IL-1) structural pathway ⁷⁴ Interleukin-33 signaling ⁶⁶ Interleukin-36 pathway ⁶⁶ Mucin expression in CF via TLRs, EGFR signaling pathways ²² Pathogen or Damage-activated C-Type Lectin Receptor Signaling Pathways ⁶⁵	12.62	TNF TLR2 MUC5B MUC5AC IL6 IL1B
7	NF-kappaB Signaling ³	12.59	TNF TLR2 IL1B IL10 CD79A
8	Toll-Like receptor Signaling Pathways ⁶⁵ Show member pathways Inflammasome Activation Pathways ⁶⁵ Nanomaterial-induced inflammasome activation ⁷⁴ NOD-like Receptor Signaling Pathways ⁶⁵ TLR4 signaling and tolerance ⁷⁴ Toll-Like Receptors Pathway ⁶⁴	12.57	TNF TLR4 TLR2 IL6 IL1B CXCL8
9	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.35	TNF TLR4 IL6 IL1B CXCL8
10	Bacterial infections in CF airways ²² Show member pathways Altered glycosylation of MUC1 in tumor microenvironment ⁷⁴ IL-1 beta-dependent CFTR expression ²² IL1-mediated signaling events ⁶¹ Immune response Bacterial infections in normal airways ²² Immune response TLR signaling pathways ²² NTHi-Induced Signaling ⁶⁴ Signal transduction through IL1R ⁷⁴	12.31	CCL11 CXCL8 IL1B IL6 TLR2 TLR4
11	IL-17 Family Signaling Pathways ⁶⁵ Show member pathways IL17 signaling pathway ⁶⁷ IL-17 signaling pathway ⁷⁴ Mucin expression in CF via IL-6, IL-17 signaling pathways ²²	12.3	TNF TLR2 MUC5B MUC5AC IL6 CXCL8
12	Sudden infant death syndrome (SIDS) susceptibility pathways ⁷⁴	12.23	TNF IL6 IL1B IL10 CXCL8
13	Colorectal Cancer Metastasis ⁶⁴	12.2	TNF TLR4 TLR2 IL6
14	Neuroinflammation and glutamatergic signaling ⁷⁴	12.12	TNF IL6 IL1B IL10
15	Spinal cord injury ⁷⁴	12.06	CXCL8 IL1B IL6 TLR4 TNF
16	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	12.02	TNF IL6 IL10 CD79A
17	Allograft rejection ⁷⁴	11.92	TNF IL1B IL10 CXCL8
18	Th17 Differentiation ⁶⁵ Show member pathways IL-21 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.91	TLR4 TLR2 IL6 IL1B
19	Cytokine production by Th17 cells in CF (Mouse model) ²² Show member pathways Cytokine production by Th17 cells in CF ²²	11.85	TLR4 IL6 CXCL8
20	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.81	TNF IL6 IL1B IL10
21	Innate Lymphoid Cells Differentiation ⁶⁵	11.78	TNF IL1B IL10
22	Burn wound healing ⁷⁴	11.78	CXCL8 IL1B IL6 TLR4 TNF
23	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.77	TNF IL6 IL1B IL10 CXCL8 CCL11
24	Acute viral myocarditis ⁷⁴	11.75	TLR4 IL6 IL10
25	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.73	TNF IL6 IL1B CXCL8
26	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.73	TNF TLR4 IL6 IL10 CD79A
27	AP-1 transcription factor network ⁶¹	11.71	IL6 IL10 CXCL8
28	miRNAs involvement in the immune response in sepsis ⁷⁴	11.65	TNF TLR4 IL6 IL10 CXCL8
29	Non-genomic actions of 1,25 dihydroxyvitamin D3 ⁷⁴	11.63	TNF TLR4 IL6 CXCL8
30	IL27-mediated signaling events ⁶¹ Show member pathways IL12 signaling pathway ⁶⁷ Th1 Differentiation ⁶⁵	11.63	TNF TLR4 TLR2 IL6 IL1B IL10
31	IL 10 signaling pathway ⁶⁷	11.62	TNF TLR4 IL6 IL1B IL10
32	MSP-RON Signaling ⁶⁴	11.59	TNF TLR4 TLR2 IL1B
33	SARS-CoV-2 innate immunity evasion and cell-specific immune response ⁷⁴	11.57	TNF IL10 CXCL8
34	Inflammatory bowel disease signaling ⁷⁴ Show member pathways Ulcerative colitis signaling ⁷⁴	11.57	TNF TLR4 TLR2 IL6 IL10
35	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	11.51	TNF IL6 IL1B
36	Fibrin complement receptor 3 signaling pathway ⁷⁴	11.49	TNF TLR4 IL6
37	Interleukin-10 signaling ⁶⁶	11.39	TNF IL6 IL1B IL10 CXCL8
38	Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway ⁷⁴	11.36	TNF IL6 IL1B CXCL8
39	Development and heterogeneity of the ILC family ⁷⁴	11.35	TNF IL6 IL1B
40	Cytokines and inflammatory response ⁷⁴	11.34	TNF IL6 IL1B IL10
41	Prostaglandin signaling ⁷⁴	11.32	TNF IL6 IL1B CXCL8
42	Immune infiltration in pancreatic cancer ⁷⁴	11.29	TNF IL6 IL10 CXCL8
43	LDL- influence on CD14 and TLR4 ⁷⁴	11.12	TLR4 IL6 IL1B IL10
44	Overview of nanoparticle effects ⁷⁴	11.1	CXCL8 IL6 TNF
45	G-protein signaling_Rap2B regulation pathway ²²	11.04	TNF IL6 IL1B IL10 CXCL8 CCL11
46	IL-10 Pathway ⁶⁴	10.9	TNF TLR4 IL6 IL1B IL10
47	Lung fibrosis ⁷⁴	10.9	TNF MUC5B IL6 IL1B CXCL8 CCL11
48	IL-9 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	10.78	IL6 IL1B
49	COVID-19 adverse outcome pathway ⁷⁴	10.7	IL6 CXCL8
50	ApoE and miR-146 in inflammation and atherosclerosis ⁷⁴	10.65	TLR4 TLR2

Sources

GO Terms for Otitis Media

Cellular components related to Otitis Media according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	10	A2ML1 CCL11 CXCL8 IL10 IL1B IL6
2	extracellular region	GO:0005576	9.64	TNF SPINK5 RNASE3 MUC5B MUC5AC MBL2

Biological processes related to Otitis Media according to GeneCards Suite gene sharing:

(show all 39)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of cell population proliferation	GO:0008285	10.38	TNF TLR2 IL6 IL1B IL10 CXCL8
2	inflammatory response	GO:0006954	10.36	CCL11 CXCL8 IL1B IL6 TLR2 TLR4
3	positive regulation of DNA-binding transcription factor activity	GO:0051091	10.25	TNF IL6 IL1B IL10
4	defense response to bacterium	GO:0042742	10.23	TNF TLR4 RNASE3 MBL2 IL10
5	positive regulation of inflammatory response	GO:0050729	10.23	TNF TLR4 TLR2 IL1B
6	cellular response to type II interferon	GO:0071346	10.21	CCL11 TLR2 TLR4 TNF
7	positive regulation of NF-kappaB transcription factor activity	GO:0051092	10.21	TNF TLR4 TLR2 IL6 IL1B
8	positive regulation of NIK/NF-kappaB signaling	GO:1901224	10.17	IL1B TLR2 TLR4 TNF
9	regulation of insulin secretion	GO:0050796	10.16	TNF IL6 IL1B
10	response to activity	GO:0014823	10.15	TNF IL6 IL10
11	positive regulation of nitric oxide biosynthetic process	GO:0045429	10.14	TNF TLR4 IL1B
12	positive regulation of interleukin-10 production	GO:0032733	10.14	IL6 TLR2 TLR4
13	positive regulation of interleukin-6 production	GO:0032755	10.13	IL1B IL6 TLR2 TLR4 TNF
14	positive regulation of receptor signaling pathway via JAK-STAT	GO:0046427	10.12	TNF IL6 IL10
15	cellular response to lipopolysaccharide	GO:0071222	10.11	TNF TLR4 IL6 IL1B IL10 CXCL8
16	liver regeneration	GO:0097421	10.1	TNF IL6 IL10
17	response to lipopolysaccharide	GO:0032496	10.09	TNF TLR4 TLR2 IL1B IL10
18	positive regulation of cytokine production involved in inflammatory response	GO:1900017	10.08	TNF TLR4 IL6
19	B cell proliferation	GO:0042100	10.07	TLR4 IL10 CD79A
20	lipopolysaccharide-mediated signaling pathway	GO:0031663	10.06	TNF TLR4 TLR2 IL1B
21	immune response	GO:0006955	10.06	TNF TLR4 TLR2 IL6 IL1B IL10
22	positive regulation of glial cell proliferation	GO:0060252	10.05	TNF IL6 IL1B
23	positive regulation of heterotypic cell-cell adhesion	GO:0034116	10.01	TNF IL1B IL10
24	positive regulation of oxidative stress-induced neuron death	GO:1903223	9.97	TNF TLR4
25	negative regulation of cytokine production involved in immune response	GO:0002719	9.97	TNF IL10
26	positive regulation of fever generation	GO:0031622	9.96	TNF IL1B
27	positive regulation of neuroinflammatory response	GO:0150078	9.95	TNF IL6 IL1B
28	sequestering of triglyceride	GO:0030730	9.94	IL1B TNF
29	positive regulation of calcidiol 1-monooxygenase activity	GO:0060559	9.92	TNF IL1B
30	positive regulation of matrix metallopeptidase secretion	GO:1904466	9.9	TLR4 TLR2
31	positive regulation of cellular response to macrophage colony-stimulating factor stimulus	GO:1903974	9.89	TLR4 TLR2
32	response to molecule of bacterial origin	GO:0002237	9.89	TLR2 IL10 CXCL8
33	chronic inflammatory response to antigenic stimulus	GO:0002439	9.88	TNF IL10
34	vascular endothelial growth factor production	GO:0010573	9.88	TNF IL6 IL1B
35	negative regulation of neurogenesis	GO:0050768	9.86	CCL11 IL1B IL6 TNF
36	positive regulation of interleukin-8 production	GO:0032757	9.85	TNF TLR4 TLR2 IL6 IL1B
37	defense response to Gram-positive bacterium	GO:0050830	9.73	TNF TLR2 RNASE3 MBL2 IL6 IL1B
38	response to external stimulus	GO:0009605	9.7	TLR4 TLR2 CXCL8
39	positive regulation of chemokine production	GO:0032722	9.28	TNF TLR4 TLR2 IL6 IL1B

Molecular functions related to Otitis Media according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	lipopolysaccharide immune receptor activity	GO:0001875	9.46	TLR4 TLR2
2	lipopolysaccharide binding	GO:0001530	9.43	TLR4 TLR2 RNASE3
3	cytokine activity	GO:0005125	9.32	TNF IL6 IL1B IL10 CXCL8 CCL11